Literature DB >> 383936

Synchronization of Plasmodium falciparum erythrocytic stages in culture.

C Lambros, J P Vanderberg.   

Abstract

Synchronous development of the erythrocytic stages of a human malaria parasite, Plasmodium falciparum, in culture was accomplished by suspending cultured parasites in 5% D-sorbitol and subsequent reintroduction into culture. Immediately after sorbitol treatment, cultures consisted mainly of single and multiple ring-form infections. At the same time, varying degrees of lysis of erythrocytes infected with the more mature stages of the parasite was evident. Approximately 95% of the parasites were in the ring stage of development at 48 and 96 hr after sorbitol treatment-likewise, a high percentage of trophozoite and schizont stages was observed at 24, 72, and 120 hr. D-Mannitol produced similar, selective, lytic effects.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 383936

Source DB:  PubMed          Journal:  J Parasitol        ISSN: 0022-3395            Impact factor:   1.276


  1195 in total

1.  Rhoptry-associated protein 1-binding monoclonal antibody raised against a heterologous peptide sequence inhibits Plasmodium falciparum growth in vitro.

Authors:  R Moreno; F Pöltl-Frank; D Stüber; H Matile; M Mutz; N A Weiss; G Pluschke
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  In vitro potentiation of antibiotic activities by a catecholate iron chelator against chloroquine-resistant Plasmodium falciparum.

Authors:  Bruno Pradines; Florence Ramiandrasoa; Jean Marc Rolain; Christophe Rogier; Joel Mosnier; William Daries; Thierry Fusai; Gerhard Kunesch; Jacques Le Bras; Daniel Parzy
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  An alteration in concatameric structure is associated with efficient segregation of plasmids in transfected Plasmodium falciparum parasites.

Authors:  R A O'Donnell; P R Preiser; D H Williamson; P W Moore; A F Cowman; B S Crabb
Journal:  Nucleic Acids Res       Date:  2001-02-01       Impact factor: 16.971

4.  Fate of haem iron in the malaria parasite Plasmodium falciparum.

Authors:  Timothy J Egan; Jill M Combrinck; Joanne Egan; Giovanni R Hearne; Helder M Marques; Skhumbuzo Ntenteni; B Trevor Sewell; Peter J Smith; Dale Taylor; Donelly A van Schalkwyk; Jason C Walden
Journal:  Biochem J       Date:  2002-07-15       Impact factor: 3.857

5.  Histidine-rich protein II: a novel approach to malaria drug sensitivity testing.

Authors:  Harald Noedl; Walther H Wernsdorfer; Robert Scott Miller; Chansuda Wongsrichanalai
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Antimalarial activities of dermaseptin S4 derivatives.

Authors:  M Krugliak; R Feder; V Y Zolotarev; L Gaidukov; A Dagan; H Ginsburg; A Mor
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

7.  16alpha-bromoepiandrosterone, an antimalarial analogue of the hormone dehydroepiandrosterone, enhances phagocytosis of ring stage parasitized erythrocytes: a novel mechanism for antimalarial activity.

Authors:  Kodjo Ayi; Giuliana Giribaldi; Aleksei Skorokhod; Evelin Schwarzer; Patrick T Prendergast; Paolo Arese
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Characterisation of PfRON6, a Plasmodium falciparum rhoptry neck protein with a novel cysteine-rich domain.

Authors:  Nicholas I Proellocks; Lev M Kats; David A Sheffield; Eric Hanssen; Casilda G Black; Karena L Waller; Ross L Coppel
Journal:  Int J Parasitol       Date:  2008-11-27       Impact factor: 3.981

Review 9.  Recent advances in malaria parasite cultivation and their application to studies on host-parasite relationships: a review.

Authors:  P I Trigg
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

10.  Influence of medium osmolality on the in vitro growth of Plasmodium falciparum: a morphologic and radioisotopic study.

Authors:  E Dei-Cas; A Wattez; A Vernes
Journal:  In Vitro Cell Dev Biol       Date:  1985-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.